CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
MK-8876drug
Likely dose
MK-8876 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01930058
NCT01930058Phase 1Completed
CompareCT.gov

A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients

Merck Sharp & Dohme LLC·interventional·Posted Aug 28, 2013·Updated Oct 25, 2018

In Brief

A Phase 1 clinical trial evaluating MK-8876 for Hepatitis C. Completed, enrolled 9 participants.

Detailed Summary

This adaptive design study will evaluate the safety, pharmacokinetics, and effect on hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV infection. The study will consist of 4 parts evaluating participants infected with specific hepatitis C virus genotypes and up to 10 panels allowing for additional participants to enroll in each panel as specified in the study analysis. The hypothesis evaluated in the study is that a ≥2.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple dose administration of MK-8876 in participants with HCV infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 28, 2013
Enrollment StartOct 2, 2013
Primary CompletionMay 5, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.8 years ago

Interventions

MK-8876drug

MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.